Skip to content

000513.SZ

Livzon Pharmaceutical Group, Inc.

SZSE · Healthcare · C 制造业 · CN

CNY 27.83
−0.32%
Ask drillr

Year over year

Reported trailing growth

Revenue
-0.3%
EBITDA
—
EBIT
-3.8%
EPS
-3.9%
Free cash flow
+21.9%
Operating cash flow
+16.5%

Forward estimates

Based on analyst estimates

Revenue
-79.9%
EBITDA
-83.9%
EPS
-84.2%

Three-year CAGR

Revenue
-1.6%
EBITDA
+5.6%
EBIT
+7.8%
Net income
+1.9%
EPS
+3.6%
Free cash flow
+11.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026